HMGB1 antagonists and TLR4/RAGE inhibitors are two preclinical approaches to blocking this system that have demonstrated therapeutic benefits in models of traumatic brain injury, neuroinflammation, epilepsy, and cognitive decline [34]. Here, HMGB1 is linked to epilepsy.